Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Testosterone intranasal (low-dose) - Acerus Pharmaceuticals

Next Previous
Search
Drug Profile

Testosterone intranasal (low-dose) - Acerus Pharmaceuticals

Alternative Names: MPP-14; Noseafix; TBS-2; Tefina

Latest Information Update: 13 Nov 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mattern Pharmaceuticals
  • Developer Acerus Pharmaceuticals; Trimel Biopharma
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Female sexual dysfunction

Highest Development Phases

  • Phase II Anorgasmia
  • No development reported Decreased libido

Most Recent Events

  • 19 Sep 2019 Tefina™ is still in phase II trials for Anorgasmia in Australia, Canada and USA (Intranasal) (Acerus Pharmaceuticals pipeline, September 2019)
  • 05 Apr 2018 Testosterone intranasal (low-dose) - Acerus Pharmaceuticals is available for licensing as of 05 Apr 2018. www.aceruspharma.com
  • 08 Sep 2015 Trimel Pharmaceuticals is now called Acerus Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top